163 related articles for article (PubMed ID: 23065280)
1. The effect of PPARG gene polymorphisms on the risk of coronary heart disease: a meta-analysis.
Xu W; Xu J; Sun B; Chen H; Wang Y; Huang F; Xi P; Jiang J
Mol Biol Rep; 2013 Feb; 40(2):875-84. PubMed ID: 23065280
[TBL] [Abstract][Full Text] [Related]
2. The meta-analysis of the association of PPARG P12A, C161T polymorphism and coronary heart disease.
Ding S; Liu L; Zhuge QC; Yu Z; Zhang X; Xie J; Hong W; Wang S; Yang Y; Chen B
Wien Klin Wochenschr; 2012 Oct; 124(19-20):671-7. PubMed ID: 22987045
[TBL] [Abstract][Full Text] [Related]
3. Associations between PPARG polymorphisms and the risk of essential hypertension.
Cai G; Zhang X; Weng W; Shi G; Xue S; Zhang B
PLoS One; 2017; 12(7):e0181644. PubMed ID: 28727849
[TBL] [Abstract][Full Text] [Related]
4. Different effects of PPARA, PPARG and ApoE SNPs on serum lipids in patients with coronary heart disease based on the presence of diabetes.
Yilmaz-Aydogan H; Kurnaz O; Kucukhuseyin O; Akadam-Teker B; Kurt O; Eronat AP; Tekeli A; Bugra Z; Ozturk O
Gene; 2013 Jul; 523(1):20-6. PubMed ID: 23583468
[TBL] [Abstract][Full Text] [Related]
5. Quantitative assessment of the influence of PPARG P12A polymorphism on gestational diabetes mellitus risk.
Wang C; Li X; Huang Z; Qian J
Mol Biol Rep; 2013 Feb; 40(2):811-7. PubMed ID: 23054024
[TBL] [Abstract][Full Text] [Related]
6. Association between peroxisome proliferator-activated receptor-alpha, delta, and gamma polymorphisms and risk of coronary heart disease: A case-control study and meta-analysis.
Qian Y; Li P; Zhang J; Shi Y; Chen K; Yang J; Wu Y; Ye X
Medicine (Baltimore); 2016 Aug; 95(32):e4299. PubMed ID: 27512842
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: a case-cohort study and meta-analyses.
Zafarmand MH; van der Schouw YT; Grobbee DE; de Leeuw PW; Bots ML
Vasc Health Risk Manag; 2008; 4(2):427-36. PubMed ID: 18561518
[TBL] [Abstract][Full Text] [Related]
8. Association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma gene and strength athlete status.
Maciejewska-Karlowska A; Sawczuk M; Cieszczyk P; Zarebska A; Sawczyn S
PLoS One; 2013; 8(6):e67172. PubMed ID: 23799144
[TBL] [Abstract][Full Text] [Related]
9. Association of the peroxisome proliferator-activated receptor-gamma2 Pro12Ala but not the C1431T gene variants with lower body mass index in Type 2 diabetes.
Mohamed MB; Mtiraoui N; Ezzidi I; Chaieb M; Mahjoub T; Almawi WY
J Endocrinol Invest; 2007 Dec; 30(11):937-43. PubMed ID: 18250615
[TBL] [Abstract][Full Text] [Related]
10. PON2 and PPARG polymorphisms as biomarkers of risk for coronary heart disease.
González-Castro TB; Tovilla-Zárate CA; Juárez-Rojop IE; Hernández-Díaz Y; López-Narváez ML; Rodríguez-Pérez C; González-Hernández YK; Ramos-Méndez MÁ
Biomark Med; 2018 Mar; 12(3):287-297. PubMed ID: 29441810
[TBL] [Abstract][Full Text] [Related]
11. Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without Type 2 diabetes.
Yilmaz-Aydogan H; Kurnaz O; Kurt O; Akadam-Teker B; Kucukhuseyin O; Tekeli A; Isbir T
Mol Cell Biochem; 2011 Dec; 358(1-2):355-63. PubMed ID: 21833536
[TBL] [Abstract][Full Text] [Related]
12. Association of the variants in the PPARG gene and serum lipid levels: a meta-analysis of 74 studies.
Li Q; Chen R; Bie L; Zhao D; Huang C; Hong J
J Cell Mol Med; 2015 Jan; 19(1):198-209. PubMed ID: 25265984
[TBL] [Abstract][Full Text] [Related]
13. Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population.
Ho JS; Germer S; Tam CH; So WY; Martin M; Ma RC; Chan JC; Ng MC
Diabetes Res Clin Pract; 2012 Sep; 97(3):483-91. PubMed ID: 22515931
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor gamma/Pro12Ala polymorphism and peroxisome proliferator-activated receptor gamma coactivator-1 alpha/Gly482Ser polymorphism in patients with sarcoidosis.
Maver A; Medica I; Salobir B; Tercelj-Zorman M; Sabovic M; Petrovic D; Peterlin B
Sarcoidosis Vasc Diffuse Lung Dis; 2008 Sep; 25(1):29-35. PubMed ID: 19070258
[TBL] [Abstract][Full Text] [Related]
15. PPARG, AGTR1, CXCL16 and LGALS2 polymorphisms are correlated with the risk for coronary heart disease.
Tian J; Hu S; Wang F; Yang X; Li Y; Huang C
Int J Clin Exp Pathol; 2015; 8(3):3138-43. PubMed ID: 26045830
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma polymorphisms and coronary heart disease.
Dallongeville J; Iribarren C; Ferrières J; Lyon L; Evans A; Go AS; Arveiler D; Fortmann SP; Ducimetière P; Hlatky MA; Amouyel P; Southwick A; Quertermous T; Meirhaeghe A
PPAR Res; 2009; 2009():543746. PubMed ID: 20016803
[TBL] [Abstract][Full Text] [Related]
17. Associations of Leptin Receptor and Peroxisome Proliferator-Activated Receptor Gamma Polymorphisms with Polycystic Ovary Syndrome: A Meta-Analysis.
Liang J; Lan J; Li M; Wang F
Ann Nutr Metab; 2019; 75(1):1-8. PubMed ID: 31412346
[TBL] [Abstract][Full Text] [Related]
18. PPARG Pro12Ala Polymorphism with CKD in Asians: A Meta-Analysis Combined with a Case-Control Study-A Key for Reaching Null Association.
Chen HC; Chen WT; Sung TL; Tsai DJ; Lin C; Su H; Lin YF; Chiu HY; Su SL
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32604723
[TBL] [Abstract][Full Text] [Related]
19. Association between the Pro12Ala polymorphism of PPAR-γ gene and the non-alcoholic fatty liver disease: a meta-analysis.
Wang J; Guo X; Wu P; Song J; Ye C; Yu S; Zhang J; Dong W
Gene; 2013 Oct; 528(2):328-34. PubMed ID: 23891820
[TBL] [Abstract][Full Text] [Related]
20. Effects of Pro12Ala polymorphism in peroxisome proliferator-activated receptor-γ2 gene on metabolic syndrome risk: a meta-analysis.
Zhang R; Wang J; Yang R; Sun J; Chen R; Luo H; Liu D; Cai D
Gene; 2014 Feb; 535(1):79-87. PubMed ID: 24012868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
